Dr Catherine Mummery On Ucl S Groundbreaking Research Into Gene She is leading a world first trial involving a ‘gene silencing’ drug (biib080) that has shown promise in safely and successfully lowering levels of the harmful tau protein known to cause alzheimer’s disease. Uclh’s trial of the world’s first ‘gene silencing’ drug for alzheimer’s disease has progressed into a larger and later stage trial, after promising early results.
Dr Catherine Mummery On Ucl S Groundbreaking Research Into Gene The trial, led by consultant neurologist dr catherine mummery at the national hospital for neurology and neurosurgery, represents the first time that a ‘gene silencing’ approach has been taken in dementia and in ad. The trial, led by consultant neurologist dr catherine mummery (ucl queen square institute of neurology & the national hospital for neurology and neurosurgery), represents the first time. A world first trial at ucl and uclh led by dr catherine mummery (ucl queen square institute of neurology) has found a new genetic therapy for alzheimer’s disease that is able to safely and successfully lower levels of the harmful tau protein known to cause the disease. The trial, led by consultant neurologist dr catherine mummery (ucl queen square institute of neurology & the national hospital for neurology and neurosurgery), represents the first time that a ‘gene silencing’ approach has been taken in dementia and alzheimer’s disease.
Dr Catherine Mummery On Ucl S Groundbreaking Research Into Gene A world first trial at ucl and uclh led by dr catherine mummery (ucl queen square institute of neurology) has found a new genetic therapy for alzheimer’s disease that is able to safely and successfully lower levels of the harmful tau protein known to cause the disease. The trial, led by consultant neurologist dr catherine mummery (ucl queen square institute of neurology & the national hospital for neurology and neurosurgery), represents the first time that a ‘gene silencing’ approach has been taken in dementia and alzheimer’s disease. The trial represents the first time a type of gene silencing therapy called rna interference has been used to target a brain disease. rna interference is one of the most promising advances in drug development today. The new treatment that is in clinical trial phase at the university college london (ucl) and university college london hospitals (uclh) is using a genetic therapy to safely lower levels of the harmful tau protein known to cause the disease. A world first clinical trial at srt grantee ucl queen square institute of neurology has shown “very promising” results for a new alzheimer’s drug that “silences” the gene coded to produce tau – a protein which can form abnormal “tangles” thought to cause alzheimer’s.
Comments are closed.